Le Lézard
Classified in: Health, Covid-19 virus
Subject: WOM

Densitas Announces Presentations at RSNA, Research Validates intelliMammotm for Mammography Quality Improvement


HALIFAX, NS, Nov. 9, 2022 /CNW/ - Densitas® Inc., a global provider of A.I. solutions for digital mammography and breast screening, announced that three quality improvement studies will be presented at the Radiological Society of North America (RSNA) 2022 Annual Scientific Meeting in Chicago.

In breast cancer screening, diagnostic confidence and breast cancer detection are predicated on having high quality images. Prior audits have shown that as many as 50% of mammograms do not meet image quality standards, 80% of which are due to poor positioning.

The three Quality Improvement Report presentations evaluate the densitas® intelliMammotm A.I. tool for mammography quality improvement.

Information on the abstracts is as follows:

Can A.I. Support Mammography Image Quality Improvement?
Primary Author: Georgia Spear, MD
Date/Time: Tuesday, November 29, 2022/ 9:00am - 9:30am (Central)
Location: Learning Center ? QI DPS

Evidence-based assessment of quality improvement in positioning requires benchmarking of population-level error rates against which quality improvement initiatives can be evaluated. Non-subjective and standardized quality assessment is foundational to benchmarking. As a first step towards establishing population-based benchmarks of mammography positioning error rates at NorthShore University HealthSystem, this study seeks to validate the ability of an A.I. tool that generates standardized positioning quality assessments to capture the expected associations between positioning errors and varying patient and acquisition parameters. The results of the study show that breast density, breast volume, breast area, breast thickness, and compression pressure were associated with numerous positioning errors.

Investigating the Feasibility of Using A.I. For Population-Level Mammography Image Quality Improvement Initiatives at Leeds Teaching Hospitals NHS Trust
Primary Author: Nisha Sharma, MBChD, FRCR
Date/Time: Wednesday, November 30, 2022/ 12:45pm - 1:15pm (Central)
Location: Learning Center ? QI DPS

The study investigates the current state of mammography image quality in breast imaging services at Leeds Teaching Hospitals NHS Trust and presents results on the reliability and reproducibility of A.I.-generated, population-based error rates and agreement between radiographers and the A.I. tool. The results of the study show that agreement between radiographers and the A.I. tool was excellent to nearly perfect, and A.I.-generated positioning error rates were consistent with reported error rates in the literature.

Driving mammography Image Quality Improvement Using A.I. in Guyana During the COVID-19 Pandemic
Primary Author: Mohamed Abdolell, MSc
Date/Time: Sunday, November 27, 2022/ 12:15 pm - 12:45 pm (Central)
Location: Learning Center ? QI DPS

This study evaluates the impact of the adoption of an A.I. tool on mammography image quality in Georgetown General Hospital, Guyana, a radiologically underserved low- and middle-income country. The results of the study show that after adoption of the A.I. tool, positioning error rates decreased substantially and MIT?radiologist communications improved to guide effective remote mammography positioning training.

Densitas® will demonstrate intelliMammotm at the upcoming Radiological Society of North America (RSNA) annual meeting, November 27?30, 2022 (Booth #2605, South Hall Level 3).

About Densitas®

Densitas® is a global leader in artificial intelligence solutions for breast cancer screening, focused on quality, safety, efficiency, and precision breast health. Densitas® designs intuitive solutions that boost the ability of hospitals and imaging centers that perform mammography to improve efficiencies, meet FDA/ACR compliance requirements, and support early breast cancer detection and treatment. For more information, visit www.densitashealth.com.

SOURCE Densitas Inc.


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: